Table of Contents

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 10-Q

 
 
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2015
 
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number: 000-33001
 
 
NATUS MEDICAL INCORPORATED
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
 
77-0154833
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
6701 Koll Center Parkway, Suite 120, Pleasanton, CA 94566
(Address of principal executive offices) (Zip Code)
(925) 223-6700
(Registrant’s telephone number, including area code)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.:
Large Accelerated filer
 
ý
  
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
o  (Do not check if a smaller reporting company)
  
Smaller reporting company
 
¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  ý
The number of issued and outstanding shares of the registrant’s Common Stock, $0.001 par value, as of October 29, 2015 was 33,021,474.


Table of Contents

NATUS MEDICAL INCORPORATED
TABLE OF CONTENTS
 
 
Page No.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

-2-

Table of Contents

PART I.    FINANCIAL INFORMATION
Item 1.    Financial Statements
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands, except share and per share amounts)
 
September 30, 2015
 
December 31, 2014
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
82,201

 
$
66,558

Accounts receivable, net of allowance for doubtful accounts of $4,598 in 2015 and $4,324 in 2014
88,905

 
82,277

Inventories
46,108

 
40,051

Prepaid expenses and other current assets
18,861

 
17,408

Deferred income tax
11,448

 
11,511

Total current assets
247,523

 
217,805

Property and equipment, net
17,976

 
17,923

Intangible assets, net
87,187

 
92,761

Goodwill
108,401

 
96,316

Other assets
8,795

 
10,016

Total assets
$
469,882

 
$
434,821

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
24,199

 
$
21,371

Accrued liabilities
39,193

 
36,024

Deferred revenue
10,191

 
11,745

Total current liabilities
73,583

 
69,140

Long-term liabilities:
 
 
 
Other liabilities
6,883

 
4,859

Deferred income tax
8,655

 
8,107

Total liabilities
89,121

 
82,106

Stockholders’ equity:
 
 
 
Common Stock, $0.001 par value, 120,000,000 shares authorized; shares issued and outstanding 32,955,830 in 2015 and 32,649,158 in 2014
318,414

 
315,296

Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2015 and 2014

 

Retained earnings
98,270

 
68,890

Accumulated other comprehensive loss
(35,923
)
 
(31,471
)
Total stockholders’ equity
380,761

 
352,715

Total liabilities and stockholders’ equity
$
469,882

 
$
434,821

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-3-

Table of Contents

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(unaudited)
(in thousands, except per share amounts)
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Revenue
$
94,583

 
$
89,876

 
$
275,915

 
$
261,824

Cost of revenue
35,520

 
33,180

 
104,468

 
102,659

Intangibles amortization
683

 
1,054

 
2,048

 
2,257

Gross profit
58,380

 
55,642

 
169,399

 
156,908

Operating expenses:
 
 
 
 
 
 
 
Marketing and selling
22,495

 
20,123

 
65,345

 
62,815

Research and development
7,700

 
7,462

 
21,867

 
22,272

General and administrative
10,031

 
12,740

 
33,239

 
34,537

Intangibles amortization
2,036

 
(408
)
 
5,165

 
1,374

Restructuring
42

 
2,848

 
358

 
3,701

Total operating expenses
42,304

 
42,765

 
125,974

 
124,699

Income from operations
16,076

 
12,877

 
43,425

 
32,209

Other income (expense), net
7

 
(1,447
)
 
(1,203
)
 
(340
)
Income before provision for income tax
16,083

 
11,430

 
42,222

 
31,869

Provision for income tax expense
5,151

 
3,607

 
12,842

 
9,830

Net income
$
10,932

 
$
7,823

 
$
29,380

 
$
22,039

Foreign currency translation adjustment
(642
)
 
(5,979
)
 
(4,452
)
 
(9,949
)
Comprehensive income
$
10,290

 
$
1,844

 
$
24,928

 
$
12,090

Earnings per share:
 
 
 
 
 
 
 
Basic
$
0.34

 
$
0.25

 
$
0.91

 
$
0.70

Diluted
$
0.33

 
$
0.24

 
$
0.89

 
$
0.68

Weighted average shares used in the calculation of earnings per share:
 
 
 
 
 
 
 
Basic
32,432

 
31,584

 
32,279

 
31,358

Diluted
33,253

 
32,615

 
33,194

 
32,426

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-4-

Table of Contents

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
(in thousands)
 
Nine Months Ended 
 September 30,
 
2015
 
2014
Operating activities:
 
 
 
Net income
$
29,380

 
$
22,039

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Provision for losses on accounts receivable
945

 
561

Excess tax benefit on the exercise of stock options
(5,304
)
 
(3,846
)
Depreciation and amortization
11,346

 
8,567

Impairment of property and equipment

 
2,160

Warranty reserve
4,771

 
1,420

Share-based compensation
5,382

 
4,704

Changes in operating assets and liabilities:
 
 
 
Accounts receivable
(6,681
)
 
1,250

Inventories
(7,014
)
 
(926
)
Prepaid expenses and other assets
(1,049
)
 
1,776

Accounts payable
3,237

 
(2,624
)
Accrued liabilities
(3,596
)
 
(5,851
)
Deferred revenue
(2,049
)
 
(1,026
)
Deferred income tax
5,560

 
4,981

Net cash provided by operating activities
34,928

 
33,185

Investing activities:
 
 
 
Acquisition of businesses, net of cash acquired
(11,559
)
 
(4,925
)
Purchases of property and equipment
(2,990
)
 
(3,736
)
Purchase of intangible assets
(1,158
)
 
(964
)
Net cash used in investing activities
(15,707
)
 
(9,625
)
Financing activities:
 
 
 
Proceeds from stock option exercises and Employee Stock Purchase Program purchases
6,086

 
10,515

Excess tax benefit on the exercise of stock options
5,304

 
3,846

Repurchase of common stock
(9,352
)
 
(3,407
)
Taxes paid related to net share settlement of equity awards
(4,303
)
 
(1,960
)
Contingent consideration earn-out
(664
)
 

Payments on borrowings

 
(30,017
)
Net cash used in financing activities
(2,929
)
 
(21,023
)
Exchange rate changes effect on cash and cash equivalents
(649
)
 
(837
)
Net increase in cash and cash equivalents
15,643

 
1,700

Cash and cash equivalents, beginning of period
66,558

 
56,106

Cash and cash equivalents, end of period
$
82,201

 
$
57,806

Supplemental disclosure of cash flow information:
 
 
 
Cash paid for interest
$

 
$
364

Cash paid for income taxes
$
5,348

 
$
4,737

Non-cash investing activities:
 
 
 
Property and equipment included in accounts payable
$
200

 
$
274

Inventory transferred to property and equipment
$
797

 
$
754

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-5-

Table of Contents

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

1 - Basis of Presentation
The accompanying interim condensed consolidated financial statements of Natus Medical Incorporated (“Natus,” “we,” “us,” “our,” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
Interim financial reports are prepared in accordance with the rules and regulations of the Securities and Exchange Commission; accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. The interim financial information is unaudited, and except for the prior period correction of errors disclosed below, reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations, and cash flows for the interim periods presented. The consolidated balance sheet as of December 31, 2014 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying financial statements should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. We have made certain reclassifications to the prior period to conform to current period presentation.
Operating results for the nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 sets forth a new revenue recognition model that requires identifying the contract, identifying the performance obligations, determining the transaction price, allocating the transaction price to performance obligations and recognizing the revenue upon satisfaction of performance obligations.
The original effective date for ASU 2014-09 would have required the Company to adopt beginning in its first quarter of 2017. In July 2015, the FASB voted to amend ASU 2014-09 by approving a one-year deferral of the effective date as well as providing the option to early adopt the standard on the original effective date. Accordingly, the Company may adopt the standard in either its first quarter of 2017 or 2018. The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is currently evaluating the timing of its adoption and the impact of adopting the new revenue standard on its consolidated financial statements.

2 - Business Combinations
Global Neuro-Diagnostics
The Company acquired Global Neuro-Diagnostics ("GND") through an equity purchase on January 23, 2015. GND's service offers patients a more convenient way to complete routine diagnostic electroencephalography (“EEG") and video electromyography ("EEG") testing which can be performed at the home, hospital or physician's office. The service also provides comprehensive reporting and support to the physician. The cash consideration for

-6-

Table of Contents

GND was $11.4 million. The purchase agreement also included an earn-out condition which the Company estimates to be $3.3 million. This earn-out is contingent upon GND achieving certain revenue milestones from 2015 to 2017.
The purchase price allocation is considered preliminary, and final determination of the value of intangible assets and contingent consideration is expected during the fourth quarter of 2015 as we are in the process of finalizing the valuation of the acquired intangible assets. Final determination of the values may result in an adjustment to the preliminary purchase price allocation, with an offsetting adjustment to goodwill. Pro forma financial information for the GND acquisition is not presented as it is not considered material.
NicView
On January 2, 2015, the Company purchased the assets of NicView for cash consideration of $1.1 million. NicView provides streaming video for families with babies in the neonatal intensive care unit. The asset purchase agreement included an earn-out condition contingent upon revenue earned in 2015. The Company estimates this earn-out to be $1.4 million. Pro forma financial information for the NicView acquisition is not presented as it is not considered material.
Hearing Screening as a Service
In the first quarter of 2014, the Company entered into two asset purchase agreements for companies in the newborn hearing screening services market for cash consideration of $2.6 million. The purchase agreements also included an earn-out condition which was contingent upon annual revenue growth through 2016. This earn-out, originally estimated at $0.8 million, was settled during the second quarter of 2015 for $0.7 million. Both acquisitions support the Company’s objective to enter this market that complements our newborn hearing screening device business. This hearing screening services business operates under the name Peloton. Pro forma financial information for these two acquisitions is not presented as it is not considered material.

3 - Earnings Per Share
The components of basic and diluted EPS are as follows (in thousands, except per share amounts):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Net income
$
10,932

 
$
7,823

 
$
29,380

 
$
22,039

Weighted average common shares
32,432

 
31,584

 
32,279

 
31,358

Dilutive effect of stock based awards
821

 
1,031

 
915

 
1,068

Diluted Shares
33,253

 
32,615

 
33,194

 
32,426

Basic earnings per share
$
0.34

 
$
0.25

 
$
0.91

 
$
0.70

Diluted earnings per share
$
0.33

 
$
0.24

 
$
0.89

 
$
0.68

Shares excluded from calculation of diluted EPS

 
245

 

 
238


4 - Inventories
Inventories consist of the following (in thousands):
 
September 30, 2015
 
December 31, 2014
Raw materials and subassemblies
$
17,917

 
$
19,821

Work in process
1,755

 
1,808

Finished goods
33,287

 
26,037

Total inventories
52,959

 
47,666

Less: Non-current inventories
(6,851
)
 
(7,615
)
Inventories, current
$
46,108

 
$
40,051


-7-

Table of Contents

At September 30, 2015 and December 31, 2014, the Company has classified $6.9 million and $7.6 million, respectively, of inventories as other assets. This inventory consists primarily of service components used to repair products pursuant to warranty obligations and extended service contracts, including service components for products we are not currently selling. Management believes that these inventories will be utilized for their intended purpose.

5 – Intangible Assets
The following table summarizes the components of gross and net intangible asset balances (in thousands):
 
September 30, 2015
 
December 31, 2014
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
Intangible assets with definite lives:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Technology
$
63,568

 
$

 
$
(30,734
)
 
$
32,834

 
$
64,376

 
$

 
$
(28,195
)
 
$
36,181

Customer related
33,106

 

 
(13,629
)
 
19,477

 
31,189

 

 
(11,786
)
 
19,403

Trade names
32,068

 
(3,382
)
 
(2,049
)
 
26,637

 
32,443

 
(3,504
)
 

 
28,939

Internally developed software
15,367

 

 
(7,653
)
 
7,714

 
14,109

 

 
(6,511
)
 
7,598

Patents
2,698

 

 
(2,173
)
 
525

 
2,794

 

 
(2,154
)
 
640

Backlog
718

 

 
(718
)
 

 
719

 

 
(719
)
 

Definite-lived intangible assets
$
147,525

 
$
(3,382
)
 
$
(56,956
)
 
$
87,187

 
$
145,630

 
$
(3,504
)
 
$
(49,365
)
 
$
92,761

Finite-lived intangible assets are amortized over their weighted average lives of 17 years for technology, 13 years for customer related intangibles, 7 years for internally developed software, 7 years for trade names, and 13 years for patents.
Internally developed software consists of $13.2 million relating to costs incurred for development of internal use computer software and $2.2 million for development of software to be sold.
Amortization expense related to intangible assets with definite lives was as follows (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Technology
$
934

 
$
1,057

 
$
2,854

 
$
2,985

Customer related
689

 
294

 
2,092

 
1,247

Trade names
1,024

 

 
2,048

 

Internally developed software
434

 
321

 
1,142

 
1,049

Patents
28

 
17

 
84

 
83

Total amortization
$
3,109

 
$
1,689

 
$
8,220

 
$
5,364


Expected amortization expense related to amortizable intangible assets is as follows (in thousands):

-8-

Table of Contents

Three months ending December 31, 2015
$
3,097

2016
11,900

2017
11,616

2018
11,392

2019
10,270

2020
8,590

Thereafter
30,322

Total expected amortization expense
$
87,187


During the second quarter of 2015 we initiated a strategy to increase the brand strength of Natus by replacing acquired product trade names with Natus branded products over time. The implementation of this strategy places definite expected future lives on our acquired trade names which previously had indefinite lives. We assigned these trade names lives of seven years based on the timeline of our branding strategy. We will continue to assess the lives of these assets based on the timing and execution of this strategy. Amortization expense for trade names is recorded as a component of operating expense. This change increased the Company’s amortization expense and decreased pre-tax income by approximately $1.0 million, decreased net income by approximately $0.7 million, and decreased diluted earnings per share by $0.02 per share for the three months ended September 30, 2015. For the nine months ended September 30, 2015, this change increased the Company’s amortization expense and decreased pre-tax income by approximately $2.0 million, decreased net income by approximately $1.4 million, and decreased diluted earnings per share by $0.04 per share.

6 – Goodwill
The carrying amount of goodwill and the changes in the balance are as follows (in thousands):
December 31, 2014
$
96,316

Acquisitions
13,489

Foreign currency translation
(1,404
)
September 30, 2015
$
108,401


7 - Property and Equipment, net
Property and equipment, net consist of the following (in thousands):
 
September 30, 2015
 
December 31, 2014
Land
$
3,044

 
$
3,092

Buildings
6,462

 
6,828

Leasehold improvements
2,419

 
2,118

Office furniture and equipment
14,156

 
12,839

Computer software and hardware
9,936

 
8,821

Demonstration and loaned equipment
11,166

 
10,929

 
47,183

 
44,627

Accumulated depreciation
(29,207
)
 
(26,704
)
Total
$
17,976

 
$
17,923

Depreciation expense of property and equipment was approximately $1.0 million and $3.1 million for the three and nine months ended September 30, 2015, respectively, and approximately $1.0 million and $3.4 million for the three and nine months ended September 30, 2014, respectively.

-9-

Table of Contents


8 - Reserve for Product Warranties
We provide a warranty with our products that is generally one year in length and in some cases, regulations may require us to provide repair or remediation beyond our typical warranty period. We also sell extended service agreements on our medical device products that are generally over one year in length. If any of our products contain defects, we may be required to incur additional repair and remediation costs. Service for domestic customers is provided by Company-owned service centers that perform all service, repair, and calibration services. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.
A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. We consider a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
We expect to incur future costs to bring our NeoBLUE® phototherapy product into U.S. regulatory compliance.  We are unable to estimate the cost of the compliance effort at this time.
The details of activity in the warranty reserve are as follows (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Balance, beginning of period
$
4,408

 
$
2,688

 
$
2,753

 
$
3,142

Additions charged to expense
1,617

 
668

 
4,770

 
1,078

Reductions
(813
)
 
(646
)
 
(2,311
)
 
(1,510
)
Balance, end of period
$
5,212

 
$
2,710

 
$
5,212

 
$
2,710


9 - Share-Based Compensation
At September 30, 2015, we have two active share-based compensation plans, the 2011 Stock Awards Plan and the 2011 Employee Stock Purchase Plan. The terms of awards granted during the nine months ended September 30, 2015 and our methods for determining grant-date fair value of the awards are consistent with those described in the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014.
Detail of share-based compensation expense is as follows (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Cost of revenue
$
29

 
$
32

 
$
116

 
$
110

Marketing and selling
287

 
261

 
972

 
531

Research and development
249

 
220

 
644

 
758

General and administrative
1,326

 
1,014

 
3,650

 
3,305

Total
$
1,891

 
$
1,527

 
$
5,382

 
$
4,704

As of September 30, 2015, unrecognized compensation expense related to the unvested portion of our stock options and other stock awards was approximately $9.2 million, which is expected to be recognized over a weighted average period of 1.7 years.


-10-

Table of Contents

10 - Other Income (Expense), net
Other income (expense), net consists of (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Interest income
$
13

 
$
(28
)
 
$
28

 
$
108

Interest expense

 
(104
)
 

 
(486
)
Foreign currency gain (loss)
(80
)
 
(785
)
 
(1,571
)
 
216

Other
74

 
(530
)
 
340

 
(178
)
Total other income (expense), net
$
7

 
$
(1,447
)
 
$
(1,203
)
 
$
(340
)

11 - Income Taxes
Provision for Income Tax Expense
We recorded provisions for income tax of $5.2 million and $12.8 million for the three and nine months ended September 30, 2015, respectively. Our effective tax rate was 32.0% and 30.4% for the three and nine months ended September 30, 2015, respectively.
We recorded provisions for income tax of $3.6 million and $9.8 million for the three and nine months ended September 30, 2014, respectively. Our effective tax rate was 31.6% and 30.8% for the three and nine months ended September 30, 2014.
Our effective tax rate for the three and nine months ended September 30, 2015 differed from federal statutory tax rate primarily due to profits taxed in foreign jurisdictions with lower tax rates than the federal statutory rate. The changes in the effective tax rate for the three and nine months ended September 30, 2015 compared with the three and nine months ended September 30, 2014 are primarily attributable to forecasted shifts in the geographical mix of income.
We recorded $2.7 million net tax benefit of unrecognized tax benefits for the nine months ended September 30, 2015. Within the next twelve months, it is possible our uncertain tax benefit may change with a range of approximately zero to $0.5 million. Our tax returns remain open to examinations as follows: U.S. Federal, 2011 through 2014, U.S. States 2010 through 2013 and significant foreign jurisdictions 2010 through 2014.

12 - Restructuring Reserves
The Company has historically incurred an ongoing level of restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization resulting from acquisitions.
The balance of the restructuring reserve is included in accrued liabilities on the accompanying condensed consolidated balance sheets. Employee termination benefits are included as a part of restructuring expenses.
Activity in the restructuring reserves for the nine months ended September 30, 2015 is as follows (in thousands):
 
Personnel Related
Facility Related
Total
Balance at December 31, 2014
$
368

$

$
368

Additions
339

115

454

Reversals
(96
)

(96
)
Payments
(464
)
(115
)
(579
)
Balance at September 30, 2015
$
147

$

$
147



-11-

Table of Contents

13 - Segment, Customer and Geographic Information
We operate in one reportable segment in which we provide healthcare products and services used for the screening, detection, treatment, monitoring and tracking of common medical ailments.
Our end-user customer base includes hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Most of our international sales are to distributors who resell our products to end users or sub-distributors.
Revenue and long-lived asset information are as follows (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Consolidated Revenue:
 
 
 
 
 
 
 
United States
$
62,553

 
$
56,678

 
$
177,627

 
$
157,481

Foreign countries
32,030

 
33,198

 
98,288

 
104,343

Totals
$
94,583

 
$
89,876

 
$
275,915

 
$
261,824

 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Revenue by End Market:
 
 
 
 
 
 
 
Neurology Products
 
 
 
 
 
 
 
Devices and Systems
$
41,993

 
$
43,922

 
$
123,086

 
$
125,917

Supplies
15,286

 
14,746

 
45,603

 
45,059

Services
2,125

 

 
5,614

 

Total Neurology Revenue
59,404

 
58,668

 
174,303

 
170,976

Newborn Care Products
 
 
 
 
 
 
 
Devices and Systems
17,598

 
16,516

 
53,916

 
49,064

Supplies
12,584

 
12,854

 
37,025

 
36,733

Services
4,997

 
1,838

 
10,671

 
5,051

Total Newborn Care Revenue
35,179

 
31,208

 
101,612

 
90,848

Total Revenue
$
94,583

 
$
89,876

 
$
275,915

 
$
261,824

 
September 30, 2015
 
December 31, 2014
Property and equipment, net:
 
 
 
United States
$
6,367

 
$
5,782

Canada
5,199

 
5,538

Argentina
3,271

 
3,692

Ireland
1,974

 
1,656

Other foreign countries
1,165

 
1,255

Totals
$
17,976

 
$
17,923

During the three and nine months ended September 30, 2015 and 2014, no single customer or foreign country contributed to more than 10% of revenue.

14 - Fair Value Measurements
ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined under ASC 820 as the exit price associated with the sale of an asset or transfer of a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes the following three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value:

-12-

Table of Contents

Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 - Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
The Company does not have any financial assets or liabilities measured at fair value on a recurring basis.
The following financial instruments are not measured at fair value on the Company’s consolidated balance sheet as of September 30, 2015 and December 31, 2014, but require disclosure of their fair values: cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities. The carrying value of these financial instruments approximates fair values because of their relatively short maturity.
In the third quarter of 2014, the Company listed its facility in Mundelein, Illinois for sale. This asset was measured at fair value less cost to sell as of September 30, 2014 based on market price and is classified as a Level 2 asset. The book value of this asset on June 30, 2014 was $3.6 million. We expensed $2.2 million during the third quarter of 2014 for this impairment. As of September 30, 2015 we are carrying the asset as held for sale in other current assets on the accompanying condensed consolidated balance sheet at a value of $1.4 million.
The Company also has contingent consideration associated with earn-outs from acquisitions. Contingent consideration liabilities are classified as Level 3 liabilities, as the Company uses unobservable inputs to value them, which is a probability-based income approach. Contingent considerations are classified as accrued liabilities on our condensed consolidated balance sheet. Subsequent changes in the fair value of contingent consideration liabilities are recorded within the Company's income statement as an operating expense.
 
December 31, 2014
 
Additions
 
Payments
 
Adjustments
 
September 30, 2015
Liabilities:
 
 
 
 
 
 
 
 
 
Contingent consideration
$
812

 
$
4,705

 
$
(664
)
 
$
(148
)
 
$
4,705

Total
$
812

 
$
4,705

 
$
(664
)
 
$
(148
)
 
$
4,705

The significant unobservable inputs used in the fair value measurement of contingent consideration related to the acquisitions are annualized revenue forecasts developed by the Company’s management and the probability of achievement of those revenue forecasts. Significant increases (decreases) in these unobservable inputs in isolation would result in a significantly lower (higher) fair value measurement.

15 - Immaterial Corrections to Prior Period Financial Statements
Certain amounts previously reported in the consolidated statements of income for the three and nine months ended September 30, 2014 and statement of cash flows for the nine months ended September 30, 2014 have been restated to reflect the correction of an immaterial error as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. The error related to the amount of manufacturing labor and overhead applied to inventory. We believe the effects of the error are not material to our consolidated financial statements.
A summary of the effects of the correction of this error on our statement of income and comprehensive income for the three and nine months ended September 30, 2014 and our statement of cash flow for the nine months ended September 30, 2014 is presented in the table below (in thousands, except per share data):

-13-

Table of Contents

 
Three Months Ended September 30, 2014
 
Nine Months Ended September 30, 2014
 
Previously Reported
 
Revised
 
Previously Reported
 
Revised
Statements of Income and Comprehensive Income
 
 
 
 
 
 
 
Cost of revenue(1)
$
34,345

 
$
33,180

 
$
105,374

 
$
102,659

Gross profit
55,531

 
55,642

 
156,450

 
156,908

Income from operations
12,766

 
12,877

 
31,750

 
32,209

Income before provision for income tax
11,319

 
11,430

 
31,410

 
31,869

Provision for income tax expense
3,533

 
3,607

 
9,634

 
9,830

Net income
7,786

 
7,823

 
21,776

 
22,039

Comprehensive income
1,806

 
1,844

 
11,828

 
12,090

Net income per share, basic
$
0.25

 
$
0.25

 
$
0.69

 
$
0.70

Net income per share, diluted
$
0.24

 
$
0.24

 
$
0.67

 
$
0.68

Statement of Cash Flows
 
 
 
 
 
 
 
Net income
 
 
 
 
$
21,776

 
$
22,039

Changes in operating assets and liabilities, net of assets and liabilities acquired in acquisitions:
 
 
 
 
 
 
 
Inventories
 
 
 
 
(469
)
 
(926
)
Accrued liabilities(2)
 
 
 
 
(7,071
)
 
(5,851
)
Net cash provided by operating activities
 
 
 
 
$
33,185

 
$
33,185

(1)    In the prior periods, cost of revenue was presented inclusive of intangibles amortization.
(2)    In the prior period, accrued liabilities was presented inclusive of deferred revenue.

ITEM 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) supplements the MD&A in the Annual Report on Form 10-K for the year ended December 31, 2014 of Natus Medical Incorporated. MD&A should be read in conjunction with our condensed consolidated financial statements and accompanying footnotes, the risk factors referred to in Part II, Item 1A of this report, our Annual Report filed on Form 10-K for the year ended December 31, 2014 and the cautionary information regarding forward-looking statements at the end of this section.
Our Business
Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.
We have completed a number of acquisitions since 2003, consisting of either the purchase of a company, substantially all of the assets of a company, or individual products or product lines. In 2015 we completed two acquisitions, NicView and GND. We expect to continue to pursue opportunities to acquire other businesses in the future.
End Markets
Our products address two primary end markets:
Neurology - Includes products and services for diagnostic electroencephalography and long term monitoring, Intensive Care Unit monitoring, electromyography, sleep analysis or polysomnography, intra-operative monitoring, and diagnostic and monitoring transcranial doppler ultrasound technology.
Newborn Care - Includes products and services for newborn care including hearing screening, brain injury,

-14-

Table of Contents

thermoregulation, jaundice management, and various disposable products, as well as products for diagnostic hearing assessment for children through adult populations, and products to diagnose and assist in treating balance and mobility disorders.
Segment and Geographic Information
We operate in one reportable segment, which we have presented as the aggregation of our neurology and newborn care product families. Within this reportable segment we are organized on the basis of the healthcare products and services we provide which are used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, and sleep disorders.
Our end-user customer base includes hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Most of our international sales are to distributors, who in turn, resell our products to end users or sub-distributors.
Information regarding our sales and long-lived assets in the U.S. and in countries outside the U.S. is contained in Note 13 – Segment, Customer and Geographic Information of our condensed consolidated financial statements included in this report and is incorporated in this section by reference.
Revenue by Product Category
We generate our revenue from sales of Devices and Systems, which are generally non-recurring, and from related Supplies and Services, which are generally recurring. The products that are attributable to these categories are described in our Annual Report on Form 10-K for the year ended December 31, 2014. Revenue from Devices and Systems, Supplies, and Services, as a percent of total revenue for the three and nine months ended September 30, 2015 and 2014, is as follows:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Devices and Systems
63
%
 
67
%
 
64
%
 
67
%
Supplies
29
%
 
31
%
 
30
%
 
31
%
Services
8
%
 
2
%
 
6
%
 
2
%
Total
100
%
 
100
%
 
100
%
 
100
%
During the three and nine months ended September 30, 2015 and 2014, no single customer or foreign country contributed to more than 10% of revenue.
2015 Third Quarter Overview
Our business and operating results are driven in part by worldwide economic conditions. Our sales are significantly dependent on both capital spending by hospitals in the United States and healthcare spending by ministries of health outside the United States.
Our consolidated revenue increased $4.7 million in the third quarter ended September 30, 2015 to $94.6 million compared to $89.9 million in the third quarter of the previous year. Our revenue increases were primarily in the United States market driven by recent acquisitions and organic growth in our Newborn Care business.
Net income was $10.9 million or $0.33 per diluted share in the three months ended September 30, 2015, compared with net income of $7.8 million or $0.24 per diluted share in the same period in 2014. This increase in income was primarily the result of increased revenue and gross profit.

-15-

Table of Contents

Application of Critical Accounting Policies
We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In so doing, we must often make estimates and use assumptions that can be subjective, and, consequently, our actual results could differ from those estimates. For any given individual estimate or assumption we make, there may also be other estimates or assumptions that are reasonable.
We believe that the following critical accounting policies require the use of significant estimates, assumptions, and judgments:
Revenue recognition
Inventory carried at the lower of cost or market value
Carrying value of intangible assets and goodwill
Liability for product warranties
Share-based compensation
The use of different estimates, assumptions, or judgments could have a material effect on the reported amounts of assets, liabilities, revenue, expenses, and related disclosures as of the date of the financial statements and during the reporting period. These critical accounting policies are described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2014, under Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations.
During the second quarter of 2015 we made a change in accounting estimate related to our indefinite lived intangible assets. See Note 5 - Intangible Assets of our condensed consolidated financial statements. There have been no other changes to our critical accounting policies during the nine months ended September 30, 2015.
Results of Operations
The following table sets forth selected consolidated statement of operations data as a percentage of total revenue for the periods indicated:
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2015
 
2014
 
2015
 
2014
Revenue
100.0
%
 
100.0
 %
 
100.0
 %
 
100.0
 %
Cost of revenue
37.6
%
 
36.9
 %
 
37.9
 %
 
39.2
 %
Intangibles amortization
0.7
%
 
1.2
 %
 
0.7
 %
 
0.9
 %
Gross profit
61.7
%
 
61.9
 %
 
61.4
 %
 
59.9
 %
Operating expenses:
 
 
 
 
 
 
 
Marketing and selling
23.8
%
 
22.4
 %
 
23.7
 %
 
24.0
 %
Research and development
8.1
%
 
8.3
 %
 
7.9
 %
 
8.5
 %
General and administrative
10.6
%
 
14.2
 %
 
12.0
 %
 
13.2
 %
Intangibles Amortization
2.2
%
 
(0.5
)%
 
1.9
 %
 
0.5
 %
Restructuring
%
 
3.2
 %
 
0.1
 %
 
1.4
 %
Total operating expenses
44.7
%
 
47.6
 %
 
45.6
 %
 
47.6
 %
Income from operations
17.0
%
 
14.3
 %
 
15.8
 %
 
12.3
 %
Other expense, net
%
 
(1.6
)%
 
(0.4
)%
 
(0.1
)%
Income before provision for income tax
17.0
%
 
12.7
 %
 
15.4
 %
 
12.2
 %
Provision for income tax expense
5.4
%
 
4.0
 %
 
4.7
 %
 
3.8
 %
Net income
11.6
%
 
8.7
 %
 
10.7
 %
 
8.4
 %

-16-

Table of Contents

Revenues
The following table shows revenue by products during the three and nine months ended September 30, 2015 and September 30, 2014, in thousands:
 
Three Months Ended 
 September 30,
 
Nine Months Ended
September 30,
 
2015
 
2014
 
Change
 
2015
 
2014
 
Change
Neurology Products
 
 
 
 
 
 
 
 
 
 
 
Devices and Systems
$
41,993

 
$
43,922

 
(4
)%
 
$
123,086

 
$
125,917

 
(2
)%
Supplies
15,286

 
14,746

 
4
 %
 
45,603

 
45,059

 
1
 %
Services
2,125

 

 
 %
 
5,614

 

 
 %
Total Neurology Revenue
59,404

 
58,668

 
1
 %
 
174,303

 
170,976

 
2
 %
Newborn Care Products
 
 
 
 
 
 
 
 
 
 
 
Devices and Systems
17,598

 
16,516

 
7
 %
 
53,916

 
49,064

 
10
 %
Supplies
12,584

 
12,854

 
(2
)%
 
37,025

 
36,733

 
1
 %
Services
4,997

 
1,838

 
172
 %
 
10,671

 
5,051

 
111
 %
Total Newborn Care Revenue
35,179

 
31,208

 
13
 %
 
101,612

 
90,848

 
12
 %
Total Revenue
$
94,583

 
$
89,876

 
5
 %
 
$
275,915

 
$
261,824

 
5
 %

For the three months ended September 30, 2015, Neurology revenue increased by 1% compared to the same quarter last year. Growth in our domestic market was offset by a decline in revenue from international markets due mainly to weakness of the Euro as compared to the US Dollar. Revenue from sales of Neurology Devices and Systems decreased by 4% driven mainly by the negative impact of the strong US Dollar to international EEG, EMG and Sleep revenue.  Revenue from Supplies increased by 4%, mainly from our domestic market. The growth in Services revenue is the result of our January 2015 acquisition of Global Neuro-Diagnostics.
For the three months ended September 30, 2015, Newborn Care revenue increased by 13% compared to the same quarter last year. Geographically, the increase was primarily in our domestic market. Revenue from Devices and Systems increased by 5% compared to the same period last year. This increase is attributable to entering the video streaming market with the January 2015 acquisition of NicView. Revenue from supplies remained constant in the third quarter of 2015 as compared to the same period last year. Revenue from Services increased 172% compared to the same period last year. This increase was due to the growth of Peloton, our hearing screening service launched in the first quarter of 2014, and the growth of our Hearing Screening Coordination services.
For the nine months ended September 30, 2015, Neurology revenue increased by 2% compared to the same period last year. Growth in our domestic market was offset by a decline in revenue from international markets, due in part to weakness of the Euro as compared to the US Dollar. Revenue from sales of Devices and Systems declined 2%, mainly due to the unfavorable exchange rate impact and a decline in our Sleep business.  Revenue from Supplies remained relatively flat compared to the same period last year. The growth in Services revenue from the acquisition of Global Neuro-Diagnostics more than offset the decline in Devices and Systems revenue for the nine months ended September 30, 2015.
For the nine months ended September 30, 2015, Newborn Care revenue increased by 12% compared to the same period last year. Geographically, the increase was primarily in our domestic market. Revenue from Newborn Care Devices and Systems increased 9% compared to the same period last year and was driven by strength in our domestic market. This increase is attributable to our acquisition of NicView. Revenue from Supplies increased 2% and was primarily driven by the introduction of two new products in the hearing and phototherapy market segments. Revenue from Services increased by 111% compared to the same period last year due to the growth of Peloton and Hearing Screening Coordination services.

-17-

Table of Contents

No single customer accounted for more than 10% of our revenue in the nine months ended September 30, 2015 or September 30, 2014. Revenue from domestic sales increased 12.9% to $62.6 million for the three months ended September 30, 2015 from $56.7 million in the third quarter of 2014. Revenue from international sales decreased 6.6% to $32.0 million for the three months ended September 30, 2015 compared to $33.2 million in the third quarter of 2014. The decrease in international revenue was driven by the weakness of the Euro relative to the US Dollar and slowing international economies.
Cost of Revenue and Gross Profit
Cost of revenue and gross profit consists of (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended
September 30,
 
2015
 
2014
 
2015
 
2014
Revenue
$
94,583

 
$
89,876

 
$
275,915

 
$
261,824

Cost of revenue
35,520

 
33,180

 
104,468

 
102,659

Intangibles amortization
683

 
1,054

 
2,048

 
2,257

Gross profit
58,380

 
55,642

 
169,399

 
156,908

Gross profit percentage
61.7
%
 
61.9
%
 
61.4
%
 
59.9
%
For the nine months ended September 30, 2015, gross profit as a percentage of revenue increased 1.5% compared to the same period in the prior year. This increase in gross profit as a percentage of revenue was attributable to our acquisitions of Global Neuro-Diagnostics and Nic-View.
Operating Costs
Operating costs consist of (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended
September 30,
 
2015
 
2014
 
2015
 
2014
Marketing and selling
$
22,495

 
$
20,123

 
$
65,345

 
$
62,815

Percentage of revenue
23.8
%
 
22.4
 %
 
23.7
%
 
24.0
%
Research and development
$
7,700

 
$
7,462

 
$
21,867

 
$
22,272

Percentage of revenue
8.1
%
 
8.3
 %
 
7.9
%
 
8.5
%
General and administrative
$
10,031

 
$
12,740

 
$
33,239

 
$
34,537

Percentage of revenue
10.6
%
 
14.2
 %
 
12.0
%
 
13.2
%
Intangibles amortization
$
2,036


$
(408
)
 
$
5,165

 
$
1,374

Percentage of revenue
2.2
%
 
(0.5
)%
 
1.9
%
 
0.5
%
Restructuring
$
42

 
$
2,848

 
$
358

 
$
3,701

Percentage of revenue
%
 
3.2
 %
 
0.1
%
 
1.4
%
Marketing and Selling
Marketing and selling expenses as a percentage of revenue increased for the three months ended September 30, 2015 as compared to the same period in 2014. We increased spending in our Newborn Care business in connection with the expansion of our services businesses, Peloton and Hearing Screening Coordination.
For the nine months ended September 30, 2015, marketing and selling expenses as a percentage of revenue decreased 0.3%. This decrease was driven by exchange rate favorability offset by an increase related to the acquisition of GND and the expansion of our services business.
Research and Development

-18-

Table of Contents

Research and development expenses decreased slightly as a percentage of revenue during the three and nine months ended September 30, 2015 compared to the same periods in 2014. This decrease is attributable to a reduction in information technology overhead allocation.
General and Administrative
General and administrative expense decreased during the three and nine months ended September 30, 2015 as compared to the same periods in 2014. This decrease is attributable to various on-going efforts to create efficiencies and reduce spending.
Intangibles Amortization
Intangibles amortization increased during the three and nine months ended September 30, 2015 as compared to the same periods in 2014. During the second quarter of 2015 we initiated a strategy to increase the brand strength of Natus by replacing acquired product trade names with Natus branded products over time. The implementation of this strategy places definite expected future lives on our acquired trade names which previously had indefinite lives. We assigned these trade names lives of seven years based on the timeline of our branding strategy. We will continue to assess the lives of these assets based on the timing and execution of this strategy. Amortization expense for trade names is recorded as a component of operating expense. This change increased the Company’s amortization expense and decreased pre-tax income by approximately $1.0 million, decreased net income by approximately $0.7 million, and decreased diluted earnings per share by $0.02 per share for the three months ended September 30, 2015. For the nine months ended September 30, 2015, this change increased the Company’s amortization expense and decreased pre-tax income by approximately $2.0 million, decreased net income by approximately $1.4 million, and decreased diluted earnings per share by $0.04 per share. In addition, intangibles amortization for the three and nine months ended September 30, 2014 included prior period adjustments which reduced amortization expense.
Restructuring
Restructuring expenses decreased during the three and nine months ended September 30, 2015 compared to the same periods in 2014. In 2014 we experienced higher expense related to facilities consolidation. During the third quarter of 2014 we listed our manufacturing facility in Mundelein, Illinois for sale and recorded disposal expense of $2.2 million to reflect the difference between net realizable value and book value.
Other Income (Expense), net
Other income (expense), net consists of investment income, interest expense, net currency exchange gains and losses, and other miscellaneous income and expense. For the three months ended September 30, 2015 we reported other income of $0.0 million compared to other expense of $1.4 million for the same period in 2014. This increase is attributable to a reduction in foreign currency exchange losses as rates remained relatively constant during the third quarter of 2015. For the nine months ended September 30, 2015 we reported other expense of $1.2 million compared to other expense of $0.3 million for the same period in 2014. This increase in expense is attributable to an increase in net currency exchange losses driven by the weakness of the Euro. These losses were offset by a reduction in interest expense in 2015 as we repaid our outstanding term loan during the fourth quarter of 2014.
Provision for Income Tax
We recorded provisions for income tax of $5.2 million and $12.8 million for the three and nine months ended September 30, 2015, respectively. Our effective tax rate was 32.0% and 30.4% for the three and nine months ended September 30, 2014, respectively.
We recorded provisions for income tax of $3.6 million and $9.8 million for the three and nine months ended September 30, 2015, respectively. Our effective tax rate was 31.6% and 30.8% for the three and nine months ended September 30, 2014.

-19-

Table of Contents

Our effective tax rate for the three and nine months ended September 30, 2015 differed from federal statutory tax rate primarily due to profits taxed in foreign jurisdictions with lower tax rates than the federal statutory rate. The changes in the effective tax rate for the three and nine months ended September 30, 2015 compared with the three and nine ended September 30, 2014 are primarily attributable to forecasted shifts in the geographical mix of income.
We recorded $2.7 million net tax benefit of unrecognized tax benefits for the nine months ended September 30, 2015. Within the next twelve months, it is possible our uncertain tax benefit may change with a range of approximately zero to $0.5 million. Our tax returns remain open to examinations as follows: U.S. Federal, 2011 through 2014, U.S. States 2010 through 2013 and significant foreign jurisdictions 2010 through 2014.

Liquidity and Capital Resources
Liquidity and capital resources consist of (in thousands):
 
September 30, 2015
 
December 31, 2014
Cash and cash equivalents
$
82,201

 
$
66,558

Working capital
173,940

 
148,665

 
Nine Months Ended 
 September 30,
 
2015
 
2014
Net cash provided by operating activities
$
34,928

 
$
33,185

Net cash used in investing activities
(15,707
)
 
(9,625
)
Net cash used in financing activities
(2,929
)
 
(21,023
)
We believe that our current cash and cash equivalents and any cash generated from operations will be sufficient to meet our ongoing operating requirements for the foreseeable future.
As of September 30, 2015, we had cash and cash equivalents outside the U.S. in certain of our foreign operations of $63.9 million. We intend to permanently reinvest the cash held by our foreign subsidiaries. If, however, a portion of these funds were needed for and distributed to our operations in the United States, we would be subject to additional U.S. income taxes and foreign withholding taxes. The amount of taxes due would depend on the amount and manner of repatriation, as well as the country from which the funds were repatriated.
On October 9, 2015 the Company entered into a Credit Agreement with Citibank, National Association (“Citibank”). Pursuant to the terms of the Credit Agreement, Citibank agrees, on a non-committed basis, to make loans to the Company from time to time, not to exceed at any time the aggregate principal amount of $25.0 million. The proceeds under the Revolving Line of Credit shall be used by the Company for working capital and general corporate purposes. The Credit Agreement contains covenants, including covenants relating to maintenance of books and records, financial reporting and notification, compliance with laws, maintenance of properties and insurance, and limitations on guaranties, investments, issuance of debt, lease obligations and capital expenditures. The Credit Agreement provides for events of default, including failure to pay any principal or interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. Concurrent with the execution of the Credit Agreement, the Company has exited an existing and previously disclosed credit agreement between the Company and Wells Fargo, N.A. We have no other significant credit facilities. As of September 30, 2015 no amounts were outstanding.
During the nine months ended September 30, 2015 cash provided by operating activities of $34.9 million was the result of $29.4 million of net income, non-cash adjustments to net income of $17.1 million, and net cash outflows of $11.6 million from changes in operating assets and liabilities. Cash used in investing activities during

-20-

Table of Contents

the period was $15.7 million and consisted primarily of cash used in the acquisition of GND of $11.4 million, net of cash acquired, and NicView for $1.1 million. Cash used to acquire other property and equipment and intangible assets was $3.0 million and $1.2 million, respectively. Cash used in financing activities during the nine months ended September 30, 2015 was $2.9 million and consisted of $9.4 million for repurchases of common stock under our share repurchase program, $4.3 million for taxes paid related to net share settlement of equity awards, and $0.7 million for a contingent consideration payment to Tender Touch, which we acquired in 2014, offset by proceeds from stock option exercises and Employee Stock Purchase Program ("ESPP") purchases and their related tax benefits of $11.4 million.
During the nine months ended September 30, 2014 cash provided by operating activities of $33.2 million was the result of $22.0 million of net income, non-cash adjustments to net income of $13.6 million, and net cash outflows of $2.4 million from changes in operating assets and liabilities. Cash used in investing activities during the period was $9.6 million and consisted of cash used to acquire Tender Touch and Hearing Health Consultants LLC of $2.5 million, purchase accounting adjustments of $2.4 million related to the Grass acquisition, and cash used to acquire property and equipment and intangible assets of $3.7 million and $1.0 million, respectively. Cash used in financing activities during the nine months ended September 30, 2014 was $21.0 million and consisted primarily of repayment of long term debt of $30.0 million and $3.4 million for repurchases of common stock under our share repurchase program, and $2.0 million for taxes paid related to net share settlement of equity awards, partially offset by ESPP purchases and their related tax benefits of $14.4 million.
Our future liquidity and capital requirements will depend on numerous factors, including the:
 
Extent to which we make acquisitions;
Amount and timing of revenue;
Extent to which our existing and new products gain market acceptance;
Cost and timing of product development efforts and the success of these development efforts;
Cost and timing of marketing and selling activities; and
Availability of borrowings under line of credit arrangements and the availability of other means of financing.
Commitments and Contingencies
In the normal course of business, we enter into obligations and commitments that require future contractual payments. The commitments result primarily from firm, noncancellable purchase orders placed with contract vendors that manufacture some of the components used in our medical devices and related disposable supply products, as well as commitments for leased office, manufacturing, and warehouse facilities.
There are no material changes to the table of contractual obligations presented in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2014.
Off Balance Sheet Arrangements
Under our bylaws, we have agreed to indemnify our officers and directors for certain events or occurrences arising as a result of the officer or director’s serving in such capacity. We have a directors and officers’ liability insurance policy that limits our exposure and enables us to recover a portion of any future amounts paid resulting from the indemnification of our officers and directors. In addition, we enter into indemnification agreements with other parties in the ordinary course of business. In some cases we have obtained liability insurance providing coverage that limits our exposure for these other indemnified matters. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. We believe the estimated fair value of these

-21-

Table of Contents

indemnification agreements is minimal and have not recorded a liability for these agreements. During the nine months ended September 30, 2015, we had no other off-balance sheet arrangements that had, or are reasonably likely to have, a material effect on our consolidated financial condition, results of operations, or liquidity.
Recent Accounting Pronouncements
See Note 1 to our Condensed Consolidated Financial Statements for a discussion of new accounting pronouncements that affect us.
Cautionary Information Regarding Forward Looking Statements
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about Natus Medical Incorporated. These statements include, among other things, statements concerning our expectations, beliefs, plans, intentions, future operations, financial condition and prospects, and business strategies. The words “may,” “will,” “continue,” “estimate,” “project,” “intend,” “believe,” “expect,” “anticipate,” and other similar expressions generally identify forward-looking statements. Forward-looking statements in this Item 2 include, but are not limited to, statements regarding the following: our expectation regarding expansion of our international operations, our expectations regarding our new products, the sufficiency of our current cash, cash equivalents, and short-term investment balances, and any cash generated from operations to meet our ongoing operating and capital requirements for the foreseeable future, the use of debt to fund acquisitions, our expectations of earnout arrangements related to acquisitions, and our intent to acquire additional technologies, products, or businesses.
Forward-looking statements are not guarantees of future performance and are subject to substantial risks and uncertainties that could cause the actual results predicted in the forward-looking statements as well as our future financial condition and results of operations to differ materially from our historical results or currently anticipated results. Investors should carefully review the information contained under the caption “Risk Factors” contained in Part II, Item 1A of this report for a description of risks and uncertainties. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.

ITEM 3.    Quantitative and Qualitative Disclosures about Market Risk
During the nine months ended September 30, 2015, there were no significant changes to our quantitative and qualitative disclosures about market risk. Please refer to Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk included in our Annual Report on Form 10-K for the year ended December 31, 2014 for a more complete discussion on the market risks we encounter.

ITEM 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the rules of the Securities and Exchange Commission, “disclosure controls and procedures” are controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
At December 31, 2014, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures. Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure

-22-

Table of Contents

controls and procedures were not effective as of December 31, 2014. This conclusion was based on the material weakness in our internal control over financial reporting further described below.
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company’s annual or interim consolidated financial statements will not be prevented or detected on a timely basis.
Our management concluded that as of December 31, 2014 our internal control over financial reporting was not effective due to a lack of sufficient resources to effectively design, implement, and operate controls over certain accounts with an appropriate degree of precision. Specifically, the design of controls over the accounting for inventory, accounts receivable and revenue recognition for software contracts and multiple element arrangements was inadequate, which in the aggregate constituted a material weakness in our internal control over financial reporting. This material weakness resulted in misstatements of inventory in our financial statements, which were corrected prior to the issuance of our financial statements as of and for the year ended December 31, 2014.
At September 30, 2015, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures. Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were not effective as of September 30, 2015 due to the material weakness that we identified as of December 31, 2014.
Remediation Efforts to Address Material Weakness
To remediate the material weakness in our internal control over financial reporting described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, we made substantive changes to enhance the sufficiency of our resources in 2014. Specifically, we added additional resources with expertise in inventory cost accounting and have redesigned our controls to ensure the proper capitalization of overhead costs and the proper monitoring of inventory valuation. We have also added additional resources within our credit and collections group during 2014 and 2015. We have added incremental resources in 2015 to enhance the design and operating effectiveness of our controls over accounts receivable, inventory, and revenue recognition.
In addition to the changes described above, we will continue to evaluate and enhance the complement of our resources during 2015, as needed, to address the material weakness identified above. We finalized our world-wide implementation of a single ERP system during the third quarter of 2015, a project we began in 2011 to consolidate eight different systems into one global platform. The completion of this project eliminates duplicative processes and increases the capacity of our existing accounting and financial reporting resources to further focus on remediating the material weakness identified above. The material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that the controls are operating effectively.
With the oversight of senior management and our audit committee, we have taken the above steps. While our remediation efforts are in process, they have not been completed.
Changes in Internal Control over Financial Reporting
Other than the actions taken as described above under “Remediation Efforts to Address Material Weakness,” there were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations over Internal Controls
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent

-23-

Table of Contents

limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within Natus have been detected.

PART II.    OTHER INFORMATION

ITEM 1.    Legal Proceedings
We may from time to time become a party to various legal proceedings or claims that arise in the ordinary course of business. Our management reviews these matters if and when they arise and believes that the resolution of any such matters currently known will not have a material effect on our results of operations or financial position.

ITEM 1A.    Risk Factors
A description of the risks associated with our business, financial condition and results of operations is set forth in Part 1, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2014. There have been no material changes in our risks from such description.

ITEM 2.    Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information regarding repurchases by the Company of its common stock for the three months ended September 30, 2015.
Period
Total Number of Shares Purchased
 
Average Price Paid per Share
 
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
 
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
July 1, 2015 - July 31, 2015
18,915

 
$
43.02

 
18,915

 
$
19,050,034

August 1, 2015 - August 31, 2015
43,606

 
$
41.86

 
43,606

 
$
17,224,655

September 1, 2015 - September 30, 2015
29,708

 
$
40.23

 
29,708

 
$
16,029,382

Total
92,229

 
$
41.57

 
92,229

 
$
16,029,382

On June 9, 2014, the Company announced the Board of Directors authorization of the repurchase of up to $10 million of the Company’s common stock pursuant to a stock repurchase program. On June 5, 2015, the Company announced the expansion of this stock repurchase program, authorizing the repurchase of up to an additional $20 million of the Company's common stock. There is no set expiration date for the program.

-24-

Table of Contents

ITEM 6.    Exhibits
 
(a)
Exhibits
 
  
 
  
Incorporated By Reference
Exhibit
No.
  
Exhibit
  
Filing
  
Exhibit
No.
  
File Date
  
Filed
Herewith
 
 
 
 
 
 
 
10.1
 
Credit Agreement, dated as of October 9, 2015, among Natus Medical Incorporated, as the borrower, and CitiBank, N.A. as bank
 
8-K
 
10.1
 
10/14/2015
 
 
 
 
 
 
 
 
 
 
 
 
 
31.1
  
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  
 
  
 
  
 
  
X
 
 
 
 
 
 
 
31.2
  
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  
 
  
 
  
 
  
X
 
 
 
 
 
 
 
32.1
  
Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  
 
  
 
  
 
  
X
 
 
 
 
 
 
 
101
  
The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Income, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements.
  
 
  
 
  
 
  
X

-25-

Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
NATUS MEDICAL INCORPORATED
 
 
 
 
 
Dated:
November 4, 2015
 
 
By:
/s/ James B. Hawkins
 
 
 
 
 
James B. Hawkins
President and Chief Executive Officer
(Principal Executive Officer)
 
 
 
 
 
Dated:
November 4, 2015
 
 
By:
/s/ Jonathan A. Kennedy
 
 
 
 
 
Jonathan A. Kennedy
Senior Vice President and
Chief Financial Officer
(Principal Financial and
Accounting Officer)

-26-